Genomics Business Summary

Genomics BioSci & Tech. Co., Ltd. (4195.TWO) operates as Taiwan’s largest commercial genomics provider, generating revenue through a diversified model of high-throughput genetic sequencing services, clinical diagnostic testing, and the distribution of laboratory instrumentation. The company’s primary business segments include clinical genomics (focusing on non-invasive prenatal testing and oncology screening), research sequencing for academic and government projects, and a growing Contract Development and Manufacturing Organization (CDMO) arm specializing in GMP-grade oligonucleotide production. Additionally, the firm maintains a robust agency business as an exclusive distributor for Thermo Fisher Scientific in Taiwan, securing recurring revenue through the sale of proprietary reagents and consumables. Within the regional landscape, Genomics competes directly with local peers such as Kim Forest Enterprise (6645.TWO), Pharmigene (7595.TWO), and Mycenax Biotech (4726.TWO), maintaining a dominant market position through its integration into Taiwan’s National Health Insurance system and its recent 2026 transition to the Taiwan Innovation Board (TIB). The company was co-founded in 2001 by Dr. Zhou De-Yuan, a distinguished sequencing researcher from Academia Sinica who led the Rice Genome Project, and his son Joseph Chou. As of March 2026, the leadership team is headed by Chairman Meng-Hsien Chou, who has overseen the firm’s strategic pivot toward profitability and clinical-grade diagnostics, and CEO Kevin Chiang, who brings extensive experience in biotechnology commercialization. The board of directors includes independent experts such as Jei-Fu Shaw and Yu-Jen Hsiao, providing oversight on the company’s expansion into AI-driven genomic interpretation. Notable institutional backing is provided by major shareholders including Taichung Commercial Bank and Eminent III Venture Capital, reflecting strong domestic confidence in the company’s role as a foundational pillar of Taiwan’s precision medicine infrastructure.